Wire · opportunities
Weekly Recap: Hibsago FDA approval, 19% functional cure and AZUR-1 68% CR
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
GSK's Hibsago has received FDA approval for treating adults with suppressed HBV on nucleos(t)ide therapy, demonstrating a 19% functional cure rate. GSK also reported a 68% clinical complete response in its AZUR-1 phase II cancer trial and is advancing multiple oncology and diagnostic assets while adjusting for upcoming HIV patent expirations.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech startup targeting liver disease or oncology now faces new competition from GSK's latest FDA-approved and advanced clinical assets. Accelerate your differentiation or partnership talks as GSK moves to capitalise on HBV and cancer treatment markets reaching peak sales potential.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics